Comment from AmoSey Inc.

Summary: AmoSey Inc., a Canadian life sciences advisory firm, supports the FDA's initiative on drug repurposing and provides specific recommendations on candidate selection and overcoming commercial incentive barriers. They advocate for prioritizing candidates with shared biological mechanisms, utilizing human genetic evidence over pure AI outputs, and creating pathways for third-party-originated proposals to find sponsors.